ANTHEMBSEANTHEM BIOSCIENCES LTD· Pharmaceuticals & BiotechnologyMediumNeutral
Announced Mon, 27 Jul, 2026 · 10:52 IST

Q1 FY27 call: Rs 418 cr revenue, soft quarter on delivery timing shifts

Management guided margin improvementOrder pipeline disclosedInvestor Communications View source PDFExplain this filing

ANTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+2.6%Reaction day
₹769.10
prior close
₹789.35
announcement price
In-mkt
timing
Nifty Midcap 150market+1.1%+1.5% vs market
Pharmaceuticals & Biotechnology peers, median of 170sector · industry level+0.7%+1.9% vs sector

On the reaction day the stock moved 1.5 pts more than Nifty Midcap 150 and 1.9 pts more than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.5
10m
+0.4
15m
+0.1
30m
+0.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+2.6+1.1+1.5+0.7+1.9
Next day
+1.9+1.1+0.8+0.0+1.9
2d
+2.6+1.9+0.7+0.9+1.7
3d
+2.1+1.5+0.5+0.0+2.1
4d
+5.3+2.0+3.3+0.0+5.3
5d
+7.7+3.2+4.4+0.6+7.0
1w
+7.3+3.2+4.1+1.0+6.2
15d
+16.4+3.4+13.0+1.7+14.7
1m
+20.1+3.6+16.5+1.8+18.3
2m
+11.2-2.7+13.9+1.9+9.3
3m
+8.6-7.4+16.0-3.2+11.8
UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals & Biotechnology peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q1 FY27 revenue Rs 418 cr (CRDMO Rs 341 cr, Specialty Rs 78 cr). EBITDA Rs 176 cr at 39.6% margin. PAT Rs 120 cr at 27.1% margin. Net cash Rs 1,720 cr. Soft quarter due to customer delivery deferrals to H2. Mgmt confident on full-year growth, 60% order book secured. Added 1 new Big Pharma client, 10 molecules in late phase. Unit 4 Rs 1,200 cr capex by FY28. FY27 capex Rs 700 cr.

Likely market impact

Soft Q1 reflects customer delivery timing, not demand weakness. Management confident on full-year growth with strong order book and Rs 1,720 cr net cash.